Ceryvyn Therapeutics Limited (ASX:CYV)
Australia · Delayed Price · Currency is AUD 0.0100
0.00 (0.00%)
Sep 18, 2026, 4:10 PM AEST
Ceryvyn Therapeutics Company Description
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia.
The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung.
It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026.
Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
Ceryvyn Therapeutics Limited
| Country | Australia |
| Founded | 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jeremy Levin |
Contact Details
Address: 117 Camberwell Road Hawthorn East, VIC 3123 Australia | |
| Phone | 61 3 9826 0399 |
| Website | ceryvyn.com |
Stock Details
| Ticker Symbol | CYV |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000478117 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Chief Executive Officer and Chairperson |
| Hamish George | Chief Financial Officer and Joint Company Secretary |
| Dr. Stuart Mudge | Chief Operating Officer |
| Dr. Michael Gerometta Ph.D. | Chief Technology Officer |
| Rebbecca Wilcox | Senior Vice President of Preclinical and Translational Science |
| Stephanie Vipond | Joint Company Secretary |